as on September 16, 2025 at 1:29 am IST
Day's Low
Day's High
0.70%
Downside
0.51%
Upside
52 Week's Low
52 Week's High
48.04%
Downside
5.70%
Upside
Check Beone Medicines Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$38.7B
EPS (TTM)
3.3355
Dividend Yield
0.00%
PE Ratio (TTM)
0P/B Ratio
0PEG Ratio
0Return On Equity TTM
36843700.00%
Compare market cap, revenue, PE, and other key metrics of Beone Medicines Ltd with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
NA | $38.7B | NA | NA | -3.89% | |
BUY | $61.1B | 256.98% | -505.15 | -12.96% | |
BUY | $101.1B | 47.85% | 28.07 | 31.86% | |
BUY | $59.4B | -3.43% | 14.11 | 31.37% |
Search interest for Beone Medicines Ltd Stock has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Beone Medicines Ltd has shown a strong improvement in its net profit over the last three quarters. The net profit increased from -151.88 million dollars to 94.32 million dollars, marking a significant turnaround. On average, the company has experienced a remarkable increase of about 6078.9% in net profit each quarter.
Revenue Rich
Beone Medicines Ltd has shown positive revenue growth over the last two quarters. The company's revenue increased from $1.11 billion to $1.31 billion, reflecting an average increase of 15.1% per quarter.
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 118.7% return, outperforming this stock by 12.2%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 7.2%
Price Dip
In the last 7 days, ONC stock has moved down by -7.6%
Organisation | Beone Medicines Ltd |
Headquarters | Aeschengraben 27, Basel, Switzerland, 4051 |
CEO | Mr. John V. Oyler |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Marcello Damiani | Chief Technology Officer |
Ms. Eleanor Duff Ph.D. | Senior VP & Head of Corporate Communications |
Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO |
Mr. Aaron Rosenberg | Chief Financial Officer |
Mr. Wang Lai Ph.D. | Global Head of Research & Development |
Mr. Titus B. Ball | VP & Chief Accounting Officer |
Ms. Liza Heapes | Head of Investor Relations |
Dr. Xiaobin Wu Ph.D. | President, COO & GM of China |
Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder |
Mr. Chan Lee | General Counsel & Senior VP |
Beone Medicines Ltd share price today is $332.33 as on at the close of the market. Beone Medicines Ltd share today touched a day high of $334.02 and a low of $330.
Beone Medicines Ltd share touched a 52 week high of $351.27 on and a 52 week low of $172.67 on . Beone Medicines Ltd stock price today i.e. is closed at $332.33,which is 5.39% down from its 52 week high and 92.47% up from its 52 week low.
Beone Medicines Ltd market capitalisation is $0.04T as on .
Indian investors can start investing in Beone Medicines Ltd (ONC) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Beone Medicines Ltd stock (as per the Rupee-Dollar exchange rate as on ).
Based on Beone Medicines Ltd share’s latest price of $332.33 as on September 16, 2025 at 1:29 am IST, you will get 0.0301 shares of Beone Medicines Ltd. Learn more about
fractional shares .